What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2022-03-15 compared with 2021-12-14 · 36 added, 43 removed, 27 unchanged (75% of the section changed)

Other Information .

Underwriting Agreement, dated as of August 9, 2021

Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021.

Articles of Incorporation of the Company, as amended, dated October 31, 2019

Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed with the SEC on March 13, 2020.

of Amendment dated July 2, 2021, to Articles of Incorporation of the Company

Incorporated by reference from the Company’s Current Report on Form 8-K filed on July 6, 2021

Certificate of Change to Articles of Incorporation of the Company, dated July 9, 2021

Incorporated by reference to from the Company’s Current Report on Form 8-K filed on July 13, 2021

Corporate Bylaws

Incorporated by reference from the Company’s Registration Statement on Form SB-2 (File No.

333-68008) filed with the SEC on August 20, 2001.

Amendment No.

1 to the Bylaws of PharmaCyte Biotech, Inc.

Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on September 25, 2014.

Amendment No.

2 to the Bylaws of PharmaCyte Biotech, Inc.

Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on October 3, 2014.

Amendment No.

3 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s Current Report on Form 8-K on June 4, 2021

Incorporated by reference from the Company’s Current Report on Form 10-K filed on August 10, 2021

Amendment No.

4 to PharmaCyte’s Bylaws, as previously filed as Exhibit 99.2 to the Company’s Current Report on Form 8-K on July 6, 2021

Incorporated by reference from the Company’s Current Report on Form 10-K filed on August 10, 2021

Form of Common Warrant

Incorporated by reference from the Company’s

Current Report on Form 8-K filed with the SEC on August 12, 2021.

Form of Pre-Funded Warrant

Incorporated by reference from the Company’s

Current Report on Form 8-K filed with the SEC on August 12, 2021.

Form of Underwriter’s Warrant

Incorporated by reference from the Company’s

Current Report on Form 8-K filed with the SEC on August 12, 2021.

Form of Pre-Funded Common Stock Purchase Warrant

Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 23, 2021.

Form of Series A Purchase Warrant

Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 23, 2021.

Form of Placement Agent Common Stock Purchase Warrant

Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on August 23, 2021.

Securities Purchase Agreement, dated as of August 19, 2021

Incorporated by reference from the Company’s Current Report on Form

8-K filed with the SEC on August 23, 2021.

On February 13, 2022, Mr.

a member of the Board of Directors of the Company, passed away.

Yuen served as an independent member of the Board and as a member

of the Board’s Compensation Committee and Nominating Committee (of which he was the Chairman).

On February 15, 2022, the Company notified the

Nasdaq Stock Market (“Nasdaq”) of Mr.

Yuen’s death and that, because of the loss, the Company is temporarily not in

compliance with the continued listing requirements as set forth in Nasdaq Listing Rule 5605(b)(1), regarding the composition of the Board.

This is because a majority of the Board is, as a result of Mr.

Yuen’s death, not comprised of independent directors.

In accordance with Nasdaq Listing Rule 5605(b)(1)(A),

the Company has an automatic cure period in order to regain compliance.

The Company expects to regain compliance with such rule by filling

Yuen’s vacancy on the Board with a new independent director who satisfies the applicable requirements of the Nasdaq Listing

Rules prior to the expiration of the cure period provided under Nasdaq Listing Rule 5605.

Nasdaq rules require that a majority of the Board

of Directors be independent directors.

The Company is technically no longer in compliance with Nasdaq rules.

As required, the Company

filed an 8-K with the SEC on Feb.

17 disclosing this.

On February 24, 2022, the Company received a letter

from Nasdaq confirming that we are not in compliance with Nasdaq rules.

The Company expected to receive this letter.

The letter also sets

forth the cure period the Company was given to regain compliance:

the earlier of the Company’s next annual shareholders’ meeting or February 13, 2023;

if the next annual shareholders’ meeting is held before August 12, 2022, then the Company must provide evidence of compliance no later than August 12, 2022.

Articles of Incorporation of the Company, as amended

Incorporated by reference from the Company’s Quarterly Report

on Form 10-Q filed with the SEC on March 13, 2020

Bylaws of the Company, as amended.

Incorporated by reference from the Company’s Current Report on

Form 8-K filed on July 13, 2021

Principal Executive Officer Certification required by Rules 13a-14 and 15d-14as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

18 unchanged sentences

PharmaCyte Biotech, Inc.

December 14, 2021

March 15, 2022

/s/ Kenneth L.

1 unchanged sentence

(Duly Authorized Officer and Principal Executive Officer)

December 14, 2021

March 15, 2022

/s/ Carlos A.

2 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information